Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach.
Zikou LiuFiona M McCutcheonHeidi HoJoanne ChiaYunxin XiaoIsabel TippettCharithani B KeragalaGeoffrey C CloudRobert L MedcalfPublished in: Research and practice in thrombosis and haemostasis (2023)
Long-term TXA treatment does not alter brain Aβ levels or impact neurologic behavior in mice predisposed to amyloid deposition and had minor effects on the levels of inflammatory mediators. This finding supports the safety of TXA and lays the foundation for TXA as a novel treatment to reduce sICH in patients with CAA.